August 8, 2024 04:26 PM EDT

Gilead shells out $320M to J&J to buy out rare liver disease drug royalties

Max Bayer

Pharma Reporter

Gilead is spending $320 million to buy out Johnson & Johnson’s global royalties for primary biliary cholangitis drug seladelpar a week before the FDA is …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Gilead shells out $320M to J&J to buy out rare liver disease drug royalties

Max Bayer

Pharma Reporter

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

SEC probe of Illumina’s Grail deal targets sales forecasts, sources say

Bristol Myers touts LAG-3 strategy in lung cancer as it preps for showdown with Merck’s Keytruda

House passes Biosecure Act, sending Chinese biotech ban to Senate

Pfizer tees up Phase 3 test in weight management — but in an unexpected area

Arbor Biotechnologies cuts early-stage discovery work, lays off staff

GSK, iTeos rejuvenate struggling TIGIT space with positive Phase 2 Jemperli combo data in lung cancer

Gilead shells out $320M to J&J to buy out rare liv­er dis­ease drug roy­al­ties

Pharma Reporter

Sign up to read this article for free.

more like this

Viridian Therapeutics

Waltham, MA, USA

Gilead shells out $320M to J&J to buy out rare liver disease drug royalties